Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer
By G. Toyokawa, K. Masuda, Y. Daigo, Hyun-soo Cho, Masanori Yoshimatsu, M. Takawa, S. Hayami, Kazuhiro Maejima, M. Chino, Helen I. Field and 6 more. 2011
114 citations recorded by the source corpus.
BackgroundThe research emphasis in anti-cancer drug discovery has always been to search for a drug with the greatest antitumor potential but fewest side effects. This can only be achieved if the drug used is against a specific target located in the tumor cells. In this study, we evaluated Minichromosome Maintenance Protein 7 (MCM7) as a novel therapeutic target in cancer.ResultsImmunohistochemical analysis showed that MCM7 was positively stained in 196 of 331 non-small cell lung cancer (NSCLC), 21 of 29 bladder tumor and 25 of 70 liver tumor cases whereas no significant staining was observed in various normal tissues. We also found an elevated expression of MCM7 to be associated with poor prognosis for patients with NSCLC (P = 0.0055). qRT-PCR revealed a higher expression of MCM7 in clinical bladder cancer tissues than in corresponding non-neoplastic tissues (P < 0.0001), and we confirmed that a wide range of cancers also overexpressed MCM7 by cDNA microarray analysis. Suppression of MCM7 using specific siRNAs inhibited incorporation of BrdU in lung and bladder cancer cells overexpressing MCM7, and suppressed the growth of those cells more efficiently than that of normal cell strains expressing lower levels of MCM7.ConclusionsSince MCM7 expression was generally low in a number of normal tissues we examined, MCM7 has the characteristics of an ideal candidate for molecular targeted cancer therapy in various tumors and also as a good prognostic biomarker for NSCLC patients.
Subfields: Genetics, Molecular Biology, Oncology
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Ryuji Hamamoto
- Yusuke Nakamura
- N. Dohmae
- Takehiro Suzuki
- G. Toyokawa
- Hyun-soo Cho
- Makoto Nakakido
- S. Hayami
In Oncology
Citations in the corpus
- Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. (2011, background): “[29] Toyokawa G, Masuda K, Daigo Y, Cho HS, Yoshimatsu M, Takawa M, Hayami S, Maejima K, Chino M, Field HI, et al.”
- RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. (2012, methodology): “Bladder Tissue Samples and RNA Preparation Bladder tissue samples and RNA preparation were described previously [14–20].”
- The JmjC domain‐containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene (2012, methodology): “Immunohistochemical staining and tissue microarray Immunohistochemical analysis was performed using a specific polyclonal rabbit-KDM3A antibody (12835-1-AP, Proteintech Group, Chicago, IL) as described previously.(35,36) For clinical bladder and lung cancer tissue microarray, En Vision kit horseradi”